agm announcement, page-42

Swuzzle - sales will go through to the 9 hospitals - I think that is factored into the share price. However, check your estimated projections in the early Sept presentation when the time comes IMO. The cont shares and the ex price of the Director's options are perhaps giveaways. IMO, it would be illogical to not further commercially trial Ropren inside St Petersburg albeit at a cost to the Russian state health system but will it be independent?

Your blue sky is now in the distribution and marketing of your product. I am fairly sure you will hear more about this by the end of the year.

Anyway, barring potantial sales and costs of production, how much cash will SLA have in the kitty at the beginning of March in your opinion?